Evotec SE ADR (EVO) revenue breakdown
By segment, Discovery & Preclinical Development is the largest at 67% of fiscal 2025 revenue; Just - Evotec Biologics grew fastest, 79% a year over 3 years.
By product, Fee for service and FTE-based research services is the largest at 79% of fiscal 2025 revenue; Licences grew fastest, 100% a year over 6 years.
Revenue by segment
Fiscal years, as Evotec SE ADR reports them in its 10-K filings; fiscal 2025 total $777M.
| Segments | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Discovery & Preclinical Development | — | — | — | $696M | $673M | $599M | $518M | 67% |
| Just - Evotec Biologics | — | — | — | $45M | $108M | $183M | $259M | 33% |
| EVT Execute | $434M | $510M | $462M | — | — | — | — | — |
| EVT Innovate | $95M | $107M | $147M | — | — | — | — | — |
Revenue by product
Fiscal years, as Evotec SE ADR reports them in its 10-K filings; fiscal 2025 total $777M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Fee for service and FTE-based research services | $399M | $461M | $522M | $673M | $727M | $737M | $613M | 79% |
| Licences | $2M | $42,000 | $245,000 | $2M | $675,000 | $3M | $122M | 16% |
| Material re-charges to customers | $15M | $22M | $36M | $44M | $38M | $39M | $32M | 4% |
| Milestone fees | $30M | $17M | $49M | $18M | $5M | $3M | $10M | 1% |
| Other fees | $1M | $1M | $2M | $3M | $2M | $544,000 | $300,000 | 0% |
Revenue by region
Fiscal years, as Evotec SE ADR reports them in its 10-K filings; fiscal 2025 total $777M.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| USA | $195M | $248M | $329M | $408M | $459M | $446M | $432M | 56% |
| Switzerland | — | — | $24M | $22,000 | $65M | $109M | $162M | 21% |
| Rest of the world | $83M | $78M | $74M | $127M | $95M | $82M | $77M | 10% |
| United Kingdom | $78M | $94M | $105M | $115M | $86M | $93M | $62M | 8% |
| Germany | $28M | $44M | $47M | $59M | $34M | $33M | $25M | 3% |
| France | $63M | $37M | $31M | $32M | $32M | $20M | $20M | 3% |
Questions
Where does Evotec SE ADR make its money?
In fiscal 2025, by segment: Discovery & Preclinical Development $518M, Just - Evotec Biologics $259M.
From Evotec SE ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.